Floatz logo

su011248

Fibrolamellar Hepatocellular Carcinoma

Assistance Publique - Hôpitaux de ParisPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Fibrolamellar Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
(-)-SIRPIGLENASTAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2CCC
PREDNISONE TABLETS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Monomethyl Fumarate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
FILGRASTIM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Mesna
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC

View all 10 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →